Milestone Pharma up on plans to resubmit FDA application for heart drug

Milestone Pharmaceuticals

26/02/2024 14:50

** Shares of Milestone Pharmaceuticals  MIST.O  rise 21.2%
to $2.06 in morning trade
    ** MIST says it plans to resubmit application to U.S. FDA
seeking approval for its experimental drug to treat a condition
leading to abnormal heart rhythm
    ** FDA had earlier requested clarification about the time of
data recorded for adverse events
    ** Says co will restructure the data sets to facilitate
FDA's analyses
    ** Plans to submit in Q2 2024
    ** The drug candidate, etripamil, is self-administered nasal
spray for treatment of paroxysmal supraventricular tachycardia
(PSVT)
    ** Up to last close, MIST shares down ~46% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))